INNOCARE's BCL2 inhibitors are expected to be included in breakthrough therapeutic varieties.

Biological E drug time.12:24

Express News | Hong Kong stocks in the Biomedical sector continue to rise, with WUXI APPTEC increasing by over 6%, Kelun-Botai Bio rising by over 5%, and BEIGENE, WUXI BIO, and WUXI XDC all increasing by over 2%.

Breakings09:55

BEIGENE's revenue growth in 2024, narrowing losses, and core products gaining global traction.

① The company achieved a revenue of 27.214 billion yuan for the year, with a year-on-year increase of 56.19%; the net income attributable to shareholders was -4.978 billion yuan, a decrease of 17.38% from the previous year; the net income excluding non-recurring items was -5.379 billion yuan, a year-on-year decrease of 17.38%; ② The revenue share of Baiyueze and Baizean continues to expand, driving the company's revenue growth.

cls.cn09:53

WUXI APPTEC: Q1 net profit significantly increased, maintaining double-digit growth guidance for the year | Interpretations

① WUXI APPTEC's Q1 net income attributable to the parent company grew 89.1% year-on-year, mainly due to revenue growth, improved overall profitability, and the sale of WUXI XDC stocks; ② WUXI APPTEC still believes it can achieve its annual double-digit growth target.

cls.cnApr 28 21:31

Breaking! This company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws in its regular reports | Summary of after-hours announcements.

The Dongbei Group has experienced a decline of 5.85% in net income for the first quarter.

cls.cnApr 28 20:17

Significant pullback! The Innovative Drugs Sector of the Hong Kong stock market was suddenly hit by a "air raid"! What happened?

The Hong Kong stock market's Innovative Drugs Sector is experiencing a high-level adjustment.

Brokerage ChinaApr 28 19:14